Ruxolitinib was superior to investigator's choice of treatment for patients with glucocorticoid-refractory GVHD following allogeneic stem cell transplantation.
Interleukin-1β inhibition reduced incident anemia and improved hemoglobin levels in patients with baseline anemia.
Success rates were high, but so were adverse event rates.
Will point-of-care mass spectrometry be the next breakthrough in cancer resection?
Adding chemotherapy to endocrine therapy did not improve survival for patients with tumors less than 8 mm in size.
Lusutrombopag was safe and effective in an integrated analysis of two phase III trials.
Disease progression at 6 months was significantly reduced with radiotherapy versus observation.
An international panel provides guidance on prognostic variables and management strategies for COVID-19–associated coagulopathy.
Rates of recurrent VTE were noninferior with oral apixaban compared with subcutaneous dalteparin, and rates of major bleeding were similar.
Luspatercept reduced transfusion burden compared with placebo.
Metastasis-free survival was significantly longer with apalutamide than with placebo.
Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.
Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.
Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.
Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.
Survival is similar between BRCA mutation carriers versus those with sporadic disease.
Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.
Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.
First-line therapy demonstrated antitumor activity in a phase II study.
Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.